Preclinical Development of a Tolerogenic Peptide From Glutamate Decarboxylase as a Candidate for Antigen-Specific Immunotherapy in Type 1 Diabetes
There are currently no approved antigen-specific immunotherapies (ASIs) for people with type 1 diabetes (T1D). We aimed to develop a peptide for ASI for T1D based on the T1D-associated auto-antigen glutamate decarboxylase 65 (GAD65). A minimal and soluble peptide derived from GAD65 was demonstrated to induce tolerance in an HLA transgenic mouse. Our data suggest this peptide derived from the GAD65 islet protein should be tested for therapeutic potential in people with T1D who have residual β-cell function.
Authors
- David C. Wraith (ORCID: https://orcid.org/0000-0003-2147-5614)
- Sky T. H. Ng
- Alastair Copland (ORCID: https://orcid.org/0000-0003-3117-3935)
- Maher G. Nawaf (ORCID: https://orcid.org/0000-0003-2827-2967)
- Naomi Richardson (ORCID: https://orcid.org/0000-0001-9682-9857)
- Parth Narendran (ORCID: https://orcid.org/0000-0002-4583-8793)
- Heather B. Streeter (ORCID: https://orcid.org/0000-0002-3237-2170)
- Michael J. Price (ORCID: https://orcid.org/0000-0001-8892-8054)
Institutions
- University of Birmingham (GB)
Publication Details
- Journal
- Diabetes
- Published
- 2024-11-21
- DOI
- https://doi.org/10.2337/db23-0996
- Citations
- 4
- Primary Topic
- Diabetes and associated disorders
- Type
- article
- Field-Weighted Citation Impact
- 2.20
Funders
- Leona M. and Harry B. Helmsley Charitable Trust
- University Hospitals Birmingham NHS Foundation Trust
- Children's Liver Disease Foundation
- Diabetes UK